Details of the Drug
General Information of Drug (ID: DMW4X37)
| Drug Name |
Diphenylpyraline
|
||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
Allergen; Belfene; Dafen; Dayfen; Diafen; Difenilpiralina; Diphenylpyralamine; Diphenylpyralinum; Diphenylpyrilene; Hispril; Histryl; Histyn; Hystryl; Lergobine; Lyssipoll; Mepiben; Neargal; AN 1041; Difenilpiralina [INN-Spanish]; Diphenylpyraline (INN); Diphenylpyraline [INN:BAN]; Diphenylpyralinum [INN-Latin];Diphenylpyraline maleate (2:1); N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze; N-Methylpiperidyl-(4)-benzhydrylaether salzsauren salze [German]; 1-Methyl-4-piperidyl benzhydryl ether; 1-methyl-4-hydroxypiperidine benzhydryl ether; 4-(Benzhydryloxy)-1-methylpiperidine; 4-(Diphenylmethoxy)-1-methylpiperidine; 4-(benzhydryloxy)-N-methylpiperidine; 4-DIPHENYLMETHOXY-1-METHYLPIPERIDINE; 4-[(diphenylmethyl)oxy]-1-methylpiperidine; 4-benzhydryloxy-1-methylpiperidine
|
||||||||||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||||||||||
| Therapeutic Class |
Antihistamines
|
||||||||||||||||||||||||||||||
| Affected Organisms |
Humans and other mammals
|
||||||||||||||||||||||||||||||
| ATC Code | |||||||||||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 281.4 | |||||||||||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 3.9 | ||||||||||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||||||||||
| ADMET Property |
|
||||||||||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||||||||||||||
| Drug Pharmacogenomic Perturbation (DPP)NEW | Click to Jump to the Detailed DPP Information of This Drug | ||||||||||||||||||||||||||||||
| Drug ADMET Endpoint Profile (DAE)NEW | Click to Jump to the Detailed DAE Information of This Drug | ||||||||||||||||||||||||||||||
| Repurposed Drugs (RPD) | Click to Jump to the Detailed RPD Information of This Drug | ||||||||||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
![]() Drug Off-Target (DOT) |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Allergic rhinitis | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | CA08.0 | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||
References



